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Brief Definitive Report 
Transgenic Expression of the Ly49A Natural Killer Cell 
Receptor Confers Class I Major Histocompatibility Complex 
(MHC)-specific Inhibition and Prevents Bone Marrow 
Allograft Rejection 
By Werner  He ld ,  Dragana  Cado ,  and Dav id  H.  Rau le t  
From the Department ofMolecular and Cell Biology and Cancer Research Laboratory, University of 
California at Berkeley, Berkeley, California 94720 
Summary 
Natural killer (NK) cells and some T cells are endowed with receptors pecific for class I major 
histocompatibility complex (MHC) molecules that can inhibit cellular effector functions. The 
function of  the Ly49 receptor family has been studied in vitro, but no gene transfer experi- 
ments have directly established the role of  these receptors in NK cell functions. We show here 
that transgenic expression of  the H-2Dd-specific Ly49A receptor In all NK cells and T cells 
conferred class I-specific Inhibition of NK cell-mediated target cell lysis as well as of  T cell 
proliferation. Furthermore, transgene xpression prevented NK cell-mediated rejection of  allo- 
geneic H-2 d bone marrow grafts by irradiated mice. These results demonstrate he function and 
specificity of  Ly49 receptors in VlVO, and establish that their subset-specific expression is neces- 
salt for the discrimination of  MHC-dlfferent cells by NK cells in unmampulated mice. 
T wo families of  NK cell receptors with specificity ~br MHC class I molecules have been described. Immu- 
noglobulin-like killer inhibitory receptors (KIl<s) were identi- 
fied on human NK cells, whereas the structurally unrelated 
Ly49 family of  receptors, homologous to C-type lectins, 
were identified in the mouse (1, 2). The Ly49 receptor 
family comprises eight closely related genes (Ly49A-H) on 
mouse chromosome 6 (2). Expression of  Ly49 receptors is 
largely restricted to NK cells and a small fraction of  T cells 
(3-5). The Ly49A, Ly49C, and Ly49G2 receptors are each 
expressed by 20-50% of NK cells, with some cells express- 
ing two or even all three of  the receptors (6-10). Mouse 
NK cells expressing the Ly49A receptor are unable to kill 
H-2D d- and H-2Dk-expresslng tumor cell or lymphoblast 
target cells (3, 11). Evidence that Ly49A binds to D d, and 
that anti-Ly49A antibodies allow Ly49A + NK cells to kill 
Dd-expressing target cells, suggested that Ly49A is a D d- 
specific receptor that delivers an inhibitory signal to NK 
cells (3, 12, 13). NK  cell subsets expressing the Ly49C or 
Ly49G2 receptors are inhibited by distinct MHC class I 
molecules, K b for the B6 allele of  Ly49C and D d or L d for 
Ly49G2 (7, 9). 
To date, there is no evidence that genetic transfer of  
Ly49 receptors confers class I-specific inhibition. There- 
fore, the role of  Ly49 receptors in regulating the various ef- 
fector functions ascribed to NK cells remains unclear. This 
is particularly true for in vivo effector functions uch as the 
NK cell-mediated rejection of  bone marrow cells. Further- 
more, the possibility has been raised that Ly49 receptors 
play a role as accessory receptors in class I-specific inhibi- 
non, rather than as the primary determinants of  specificity 
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(14). These concerns are enhanced by the failure to date to 
isolate munne homologues of the human KIP. family of  
class I-specific inhibitory receptors. It remains possible that 
the two receptor families coexist in mice and mediate dis- 
tinct functions. To address directly the role of  Ly49A in 
class 1-specific inhibition of  NK and T cell functions, we 
have generated transgenic mice in which the Ly49A cDNA 
is expressed by all NK cells and T cells. Transgenic expres- 
sion of  Ly49A in all NK cells from H-2 b mice prevented 
these mice from rejecting an H-2 d bone marrow allograft, 
and resulted in impaired in vitro cytolysis of  tumor target 
cells expressing the D d Ly49A ligand. Furthermore, expres- 
sion of  Ly49A in T cells specifically inhibited their capacity 
to mount a proliferative response to stimulator cells that 
express class I llgands of  Ly49A. 
Materials and Methods 
Generation of Ly49A Transgenic Mice. A Ly49A cDNA clone 
was isolated from the C57BL/6 (B6)-derived thymoma EL-4 us- 
ing reverse transcriptase and the polymerase chain reaction (1KT- 
PC1K) with Ly49A-specific primers containing an EcoRI site (8). 
Compared with the published Ly49A sequence (2), our cDNA 
contained two silent base pair changes, and one change that re- 
sulted in a subsntutxon at position 106 of Met to Ile. This armno 
acid substitution, however, was also found in Ly49A cDNAs we 
isolated from B6 A-LAK cells. The Ly49A cDNA clone was sub- 
cloned into the class I promoter expression cassette (15) and in- 
jected into fertdized (B6 × CBA/J)F 2 eggs. Transgenlc founder 
mice were idennfied by Southern blotting with an Ly49A cDNA 
probe and by staining penpheral blood lymphocytes with FITC- 
labeled anti-Ly49A mAbs A1 or JR9-318. B6 backcross mice 
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were typed for H-2 expression with antibodies specific for H-2D b 
(28-14-8s) or H-2K k (15-5-5, PharMmgen, San Diego, CA). 
The allotype of the NK complex on chromosome 6 was moni- 
tored with the B6 allele-specific mAb PK136 (anti-NKl.1). The 
mice used had been backcrossed two or three times to B6 mice, 
were homozygous H-2 b/b, and were homozygous for the B6 NK 
gene complex. 
Flow Cytometry. 5 X l0 s nylon wool nonadherent spleen 
cells from individual mice were stained with PE-labeled goat 
anti-mouse IgG (Southern Bxotechnology, Birmingham AL). 
Free binding sites were saturated with mouse IgG before addanon 
ofPE-conjugated anti-CD3 (PharMingen) and biotinylated PK136 
(anti-NKl.1). The washed cells were incubated with streptavi- 
din-Tricolor (Caltag Laboratories, South San Francisco, CA) plus 
FITC-labeledJlL9-318 (anti-Ly49A) (4). Lymph node cells were 
stained with PE-conjugated anti-CD4 (PharMingen) plus FITC 
labeled anti-CD8 (Caltag). Alternatively, lymph node cells were 
stained with PE-conjugated anti-CD4, anti-CD8, or anti-Ig fol- 
lowed by FITC-labeledJ1K9-318.5 X 104 to 10 s events were an- 
alyzed on an EPICS XL (Coulter, Hialeah, FL) flow cytometer. 
Expression of Ly49A on NK cells was assessed by gating on 
NKI.1 + CD3- Ig cells. Graphics were generated using the 
WmdMi software (John Trotter, Salk Institute, La Jolla, CA). 
Killer Assay. Spleen cells were passed over nylon wool col- 
umns and nonadherent cells were cultured m P, PMI-1640 
(GIBCO BRL, Gaithersburg, MD) containing 250 ng/ml re- 
combinant interleukm-2. LAK cells were harvested at day 3, and 
incubated in duplicate for 4 h with 1 × 104 SlCr-labeled target 
cells, either R8.15 tumor cells, which express only the D b class I 
molecule, or Da-transfected R_8.15 cells (16). 
Mixed Lymphocyte Reactions. Nylon wool nonadherent lymph 
node cells were enriched for CD4 + T cells by treating the cells 
with AD4(15) (anti-CD8) ascites fired and rabbit complement, 
followed by removal of dead cells over a ficoll gradient. 1 × 10 s 
Ly49A-ex'pressing CD4 + T cells (82% pure) or control CD4 + T cells 
(87% pure) were stimulated with 2 × l0 s irradiated (2,000 cads) 
spleen cells from which T cells had been depleted with mAb JiJ 
(ann-Thy 1) and rabbit complement. No cytoklnes were added. 
After 4 d, the cultures were pulsed overnight with 0.5 IxCi 
[JH]thymidine/well. 
Bone Marrow Graft Rejection. Recipient B10.D2 and 8- to 12- 
week-old Ly49A transgenac mice or control littermates, back- 
crossed three times to B6 mace, were irradiated (950 rads from a 
137Cs source) and inoculated intravenously with 5 × 106 bone 
marrow cells from B6 or B10.D2 mice, or from [32m / B6. Re- 
cipient mice were injected lntraperltoneally five days later with 
3 I.LC1 of 12SI-labeled 5-iodo-2' deoxyuridine (12sI-UdR). Isotope 
incorporation i the recipient spleens was determined 24 h later, 
after rinsing the spleens with PBS. For NK cell depletion, recipi- 
ent mice were injected intraperitoneally 24 h prior to lrradmtion 
and bone marrow transfer with either 200 b~g of mAb PK136 
(antl-NKl.1, mouse IgG2a) or the isotype matched control mAb 
14-4-4 (anti-MHC class II E k, mouse IgG2a). 
Results and Discussion 
A mouse Ly49A cDNA clone was isolated from the 
C57BL/6 036) thymoma EL-4 and inserted into the class I 
promoter/immunoglobulin enhancer expression cassette (15) 
to generate transgenic mice. A transgenic 036 × CBA/J)F 2 
founder, with a high (>15) transgene copy number,  was 
back-crossed three times to B6 (H-2 b) mice to establish a 
transgenic line (fine No. 2). The transgenic mice and non- 
transgenic littermates contained a comparable frequency 
(Fig. 1 A) and number (1.0 + 0.4 × 106, n = 6 vs. 0,9 + 
0.3 × 10 6, n = 4, respectively) of  NK cells, indicating that 
transgene xpression did not  prevent NK cell development. 
Approximately 20% of  NK  cells in nontransgenic litter- 
mates expressed Ly49A (Fig. 1 A), similar to the proport ion 
in B6 mice (3). In contrast, virtually all NK  cells (>98.0%) 
in transgenic mice expressed Ly49A on the cell surface 
(Fig. 1 A). Importantly, the cell surface expression levels of  
Ly49A on NK cells derived from transgenic mice and non-  
transgenic littermates were not significantly different, as de- 
termined by staining with the anti-Ly49A mAbs JR9-318 
(mean fluorescence intensity (MFI) 94 + 12 vs. 105 + 7, 
respectively) or A1 (data not shown). 
The Ly49A transgene was expressed not only by NK 
cells, but also on the surface of  CD4 + and CD8 + T cells 
(Fig. 1 /3). The peripheral (Fig. 1 B) and thymic (data not  
shown) T cell compartments appeared normal, suggesting 
that the transgene did not  alter T cell development in H-2 b 
,nice. Furthermore, transgene xpression was detected on 
TCRy8 + and NK1.1 + T cells (data not shown) and at vari- 
able levels on B cells (Fig. 1 B). Transgenic macrophages 
expressed little or no Ly49A on the cell surface (data not 
shown). These results extend a prev,ous report that non-  
NK I .1  + cells can support cell surface expression of Ly49 
receptors (6, 13). 
The specificity and function of  the Ly49A transgene in 
NK cells was estabhshed by its ability to confer H-2D a- 
A Spleen 
Lit t e._rmat e LV49A.Tq 
NK1.1 
Ly49A (JR9-31 e I 
B Lymph Node 
Littermate Ly49A-Tg 
°NT  
CD8 
CD4 + CD8 + slg + 
Ly49A (JR9-318) 
Figure 1. Analysis of Ly49A 
transgemc nnce. (A) Nylon wool 
nonadherent spleen cells from 
Ly49A transgenlc m]ce and non- 
transgemc httermates contained a 
similar frequency of NK cells. 
Ly49A expression defines a sub-
set of ~20% of NK cells m non- 
transgenlc httemlates, whereas 
v]rtually all transgemc NK cells 
expressed Ly49A. (B) Compara- 
ble frequencms of CD4 + and 
CD8 + T cells were observed in 
lymph nodes from transgemc 
mice and nontransgemc htter- 
mates. Compared with unstained 
lymph node cells (filled histqcrams), 
nontransgenlc CD4 + and CD8 + 
T cells &d not express Ly49A, 
whereas all CD4 + and CD8 + T 
cells from transgenlc mice ex- 
pressed Ly49A. Ly49A levels on 
surface ]mmunoglobulln-pos]- 
tlve (slg +) B cells were variable. 
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Figure 2. Ly49A transgene expressmn confers MHC class I Da-speclfiC 
inhibmon to unfractionated NK cells The results of two independent ex- 
periments are shown. Interleukln-2 activated k]ller cells from Ly49A 
transgemc and nontransgenic littermates fficiently l sed the NK cell~en- 
stove tumor cell line R8.15, which expresses only the D b class I molecule. 
P-.8.15 cells transfected with the D d class I molecule were resistant to lysis 
by killer cells from Ly49A-transgemc ice but were lysed by killer cells 
from nontransgenic httermates 
specific inhibit ion to unfractionated interleukin-2-activated 
NK cells. Whereas NK ceils from Ly49A-transgenic mice 
(H-2 b) and control nontransgenic littermates (H-2 b) effi- 
ciently lysed the tumor  target cell II.8.15, the lytic activity 
of  transgenic NK cells was specifically inhibited by D '~ ex- 
pression as shown by their failure to lyse Dd-transfected 
R8.15 cells (Fig. 2). Similar results were obtained with 
freshly isolated, poly I /C-act ivated NK cell preparations 
(data not shown). These results represent direct evidence 
that Ly49 molecules are sufficient o confer class I-specific 
inhibit ion of  target cell lysis to NK cells. A previous study 
employing viral-mediated gene transduction reached a sim- 
ilar conclusion with respect to the structurally unrelated 
human KIlL gene family (17). 
Previous studies have demonstrated that NK  cells me&ate 
the rejection by irradiated mice of allogeneic or class I-defi- 
cient bone marrow cells, and of  parental-type marrow grafts 
by F 1 hybrids of  H -2  disparate mouse stratus (18). To estab- 
lish the role of  Ly49 receptors in NK cell specificity and 
funct ion in vivo, we determined the effects of  Ly49A 
transgene expression on the capacity of  irradiated H-2  b 
mice to reject an allogeneic H-2  d bone marrow graft, a 
reaction that is mediated by NK cells (19). Marrow engraft- 
ment  was monitored by the incorporat ion of  5-[12sI]iodo - 
2 ' -deoxyur id ine in spleen cells, indicating donor  cell pro-  
liferation (18). Whereas nontransgenic H-2  b mice rejected 
the allogeneic H-2  a (B10.D2) bone marrow grafts, Ly49A- 
transgenic H-2  b mice completely accepted these grafts, as 
demonstrated by the high level of  isotope incorporat ion in 
their spleens (Fig. 3 A). As expected, both Ly49A trans- 
gemc and nontransgenic mice accepted H-2- ident ica l  B6 
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Ly49A transgemc H-2 b mice are unable to reject an H-2 a 
bone marrow allograft. (A) P, ejectlon of bone marrow grafts by irradiated 
mice was assayed with the splemc ~2sI-UdR Incorporation assay, ,n which 
low levels of ISOtope incorporation reflect rejection of the graft, and high 
levels of incorporation reflect graft acceptance. Each symbol represents an 
Individual recipient animal Four recipient mace were used per expen- 
mental group in most cases. The transgenlc mace, like the control mace, 
accepted H-2-1dentical (H-2 b) grafts. In contrast with nontransgenlc litter- 
mates, Ly49A-transgemc H-2 b mice were unable to reject H-2 a bone 
marrow grafts This was not due to a general inability to reject bone mar- 
row cells, since grafts derived from [32m-deficient mice were readily re- 
lected (B) Bone marrow graft rejection in Ly49A transgemc mice is me- 
&ated by NK1 1 + cells since depletmn of NK1 1 + cells results m the 
inablhty to reject grafts derived from {32m-deficient mice. 
(H-2 b) bone  marrow grafts.The Ly49A-transgenic mice 
retained the capacity to reject bone marrow grafts from 
class I -def ic ient (i.e., [32m-) mice (20) (Fig. 3 A), a reac- 
non  that was prevented by pretreating the mice with anti- 
NK I .1  antibody, but  not with irrelevant (ant i -MHC class 
II I-E) antibody (Fig. 3 B). Hence, the transgene specifi- 
cally prevented rejection of  H-2 d bone marrow grafts, and 
did not affect NK-mediated rejection of  132m- bone mar- 
row grafts. This experiment demonstrates that the capacity 
to reject H-2  d grafts is prevented when Ly49A is expressed 
on all NK  ceils, as opposed to on a subset of  NK  cells as 
observed in normal mice. Therefore, a significant conclu-  
sion of our results is that the alloreactivity observed in the 
NK cell compartment is due to the failure of  many NK 
cells to express a given class I-specific inhibitory receptor, 
i.e., to the fact that Ly49 receptor expression is normally 
restricted to NK cell subsets. 
The demonstrat ion that the Ly49A transgene prevents 
rejection of  H-2  d bone marrow cell grafts provides direct 
evidence of  a role for Ly49 receptors in vivo. A role for 
Ly49 receptors in bone marrow cell rejection was previ- 
ously inferred from in vitro cytolysis experiments that mir-  
ror the specif icity of bone marrow cell re jecnon (9). Some 
caution is warranted in equating the cytolysis experiments 
with bone marrow cell rejection; however, when it is con-  
sidered that marrow rejection remains largely intact in mice 
2039 Held et al. BrlefDefimtive Report 
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Figure 4. Ly49A transgene expression mCD4 ÷ T cells prevents he al- 
logenelc mixed lymphocyte r action. CD4 + responder T ceils from B6 
backcross (H-2 b) Ly49A transgemc nnce proliferated mresponse to~2m- 
deficient B10.BR stimulator spleen cells. In contrast, he response to 
[32m + B10.BR stimulators, which express the D k Ly49A hgand, was 
strongly inhibited. CD4 + T cells from nontransgenlc httermates prohfer- 
ated in response to[32m as well as [32m + B10.13R smnulator cell popu- 
lations Data represent mean values + standard deviation of quadruphcate 
deternnnatlons based on two experiments. 
that lack perforin- or Fas-mediated cytotoxic function (21). 
Furthermore, the possibility that MHC recognition by NK 
cells can in some cases induce, rather than inhibit bone 
marrow rejection is not reflected by the in vitro assays (22, 
23). A role for Ly49 receptors in bone marrow cell rejec- 
tion was also previously suggested by correlative vidence 
that Ly49C ÷ NK cells are essential for rejection of  H-2 d 
bone marrow grafts by H-2 b mice (24). Since cells express- 
ing Ly49C are present in normal numbers in Ly49A trans- 
genic mice (data not shown), a hkely explanation of our re- 
sults is that Ly49A transgene xpression confers Dd-specific 
inhibition to all Ly49C ÷ NK cells, thus preventing these 
cells from rejecting the H-2 d bone marrow cell allograft. 
To address whether Ly49 receptors can confer class I-spe- 
cific inhibition to lymphocytes other than NK cells, we ad- 
dressed the effects of Ly49A transgene xpression on the 
proliferative response of  conventional CD4 ÷ T cells, most 
of  which are normally Ly49A- (Fig. 1 B), to allogenelc 
class II molecules. CD4 + T cell-enriched responder cells 
from transgenic and nontransgenic mice responded equiva- 
lently to stimulation with [32m-deficient B10.B1K spleen 
cells (Fig. 4). These stimulator cells present he allogeneic 
A k and E k class II molecules, but do not express class I mol-  
ecules. Stimulator cells from class I + B10.BR mice, which 
also express A k and E k but express in addition the Ly49A- 
specific D k class I molecule (11), ehcited a good response 
from nontransgenic CD4 + T cells, but the response of  the 
Ly49A-transgenic CD4 + T cells was completely inhibited. 
Thus, the Ly49A-class I interaction can even inhibit T cell 
receptor-mediated responses to allogeneic class II mole- 
cules. Similar results were obtained when we tested the 
CD8 + T cell proliferative response to allogenelc MHC 
molecules (data not shown). 
The finding that Ly49A functions in T cells indicates 
that no additional NK cell-specific molecules are required 
for Ly49 receptor activity, and suggests that the relevant in- 
hibitory signaling pathways are conserved in NK and T cells 
and perhaps all lymphoid cells. In line with this observa- 
tion, previous studies in the human system demonstrated 
KIR-mediated, class I-specific inhibition of  cytolysis by 
certain T cell clones (25). The recent implication of  the ty- 
rosine phosphatases PTP lC  and/or  PTP lD  in the down- 
modulation or prevention of  immune responses by B cells, 
T cells, and NK cells lends further support for this notion 
(26-28). With regard to Ly49A, the retention of the signal- 
ing pathway in T cells is of  particular interest because a 
small fraction o f t  cells express Ly49 receptors on their sur- 
face (4, 5). Therefore, besides regulating NK cell function, 
Ly49A-class I interactions may be important in normal 
mice for the regulation of some T cells (25). 
In conclusion, we have demonstrated that the Ly49A 
molecule is the only NK cell-specific receptor equired to 
confer inhibitory class I specificity to NK cells and T cells, 
and most significantly, that these receptors regulate NK cell 
function in vivo. The results suggest hat Ly49 receptors 
regulate multiple cellular effector functions, and do not 
represent accessory receptors for class I recognition. Fur- 
thermore, the data indicate that the expression of  Ly49 re- 
ceptors by NK cell subsets in normal mice is essential for 
the discrimination of  class I-different cells. This property is 
probably necessary to allow NK cells to attack variant cells 
in which the expression of  some but not all host class I 
molecules are repressed due to infection, mutation, or 
transformation (29). 
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